DennisP 3 days ago

So don't let people sell the drugs at a profit, at early stages.

  • kulahan 2 days ago

    Oh sick, so every time my company faces an economic downturn, I can shift huge amounts of workers to a program designed to sell unfinished drugs at cost! Like, it doesn’t even have to be viable, just start selling saline with coloring or something.

    Unless it does have to be somewhat viable, which is… regulation.

    • DennisP 2 days ago

      I'm not against regulation in principle. In this case, full disclosure of exactly what's in the drug should definitely be required. People's doctors can make informed decisions after that.

      Restricting this to patients who are otherwise out of options is probably also a good idea. Pancreatic cancer would certainly qualify.

  • Induane 3 days ago

    Ding ding ding this is the way. Sell at cost. Real cost, like cost of making. NOT a cost that includes R&S amortized across the batch.

    • vibrio 3 days ago

      Not even cost plus? Not sure how that works, from the viewpoint of economic incentives.

      • ulfw 2 days ago

        It's literally free data for efficacy / later sales.